Outcomes of Older Patients on Enfortumab Vedotin for Urothelial Carcinoma

The treatment landscape for advanced urothelial carcinoma (aUC) has undergone a significant transformation since the FDA approval of enfortumab vedotin (EV) in 2019. Although results from pivotal trials have been practice-changing, older adults were underrepresented in these studies, and data including these patients remain limited. This study compares efficacy and safety outcomes between patients aged 70 or older and those younger than 70 years receiving EV therapy, using real-world data.